Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8335694 | 0.76 | — | — | |
| SCHEMBL10104718 | 0.64 | CRBN (0.31) | CRBN | |
| SCHEMBL6938065 | 0.60 | — | — | |
| SCHEMBL6938069 | 0.60 | — | — | |
| SCHEMBL6935357 | 0.60 | — | — | |
| SCHEMBL25067267 | 0.60 | CRBN (0.42) | CRBN | |
| SCHEMBL6935363 | 0.60 | — | — | |
| SCHEMBL6935361 | 0.60 | — | — | |
| SCHEMBL13996037 | 0.58 | KMT2A (0.31) | — | |
| SCHEMBL13233498 | 0.58 | KMT2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533999-B2 | Fused thiazin-3-ones as KCA3.1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-03 | — | — | US | disclosed |
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232484-A1 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS | KCNA3, KCNK3, KCNN3 | CRBN 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.